
Opinion|Videos|March 20, 2025
Considerations for Treatment Approaches in Intermediate-Stage HCC
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how emerging evidence suggests that combining transarterial chemoembolization (TACE) with systemic therapy could redefine the standard of care for hepatocellular carcinoma (HCC). Trial outcomes may drive shifts toward more personalized locoregional approaches. However, challenges in implementation include optimizing patient selection, managing toxicity, and ensuring multidisciplinary coordination.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Considering recent evidence, how do you envision the combination of TACE and systemic therapy evolving as a potential new standard of care?
- What potential shifts could occur in locoregional treatment approaches based on trial outcomes?
- What challenges might arise in implementing these combination strategies in routine patient care?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5







































